INTERACTION OF ELONGATION FACTOR 1-ALPHA WITH LEUCINE-RICH REPEAT KINASE 2 IMPAIRS KINASE ACTIVITY AND MICROTUBULE BUNDLING IN VITRO

被引:41
|
作者
Gillardon, F. [1 ]
机构
[1] Boehringer Ingelheim Pharma GmbH & Co KG, CNS Res, D-88397 Biberach, Germany
关键词
Parkinson's disease; leucine-rich repeat kinase 2; elongation factor 1-alpha; GTPase; microtubules; dynamics; PARKINSONS-DISEASE; FACTOR; 1A; ROC DOMAIN; LRRK2; PROTEIN; GTPASE; LEUCINE-RICH-REPEAT-KINASE-2; TRANSLOCATION; CYTOSKELETON; DEGRADATION;
D O I
10.1016/j.neuroscience.2009.06.051
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Autosomal dominant mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common genetic cause of late-onset Parkinson's disease. However, the regulators/effectors contributing to the (patho-)physiological functions of LRRK2 remain poorly defined. Here we show that human LRRK2 co-purifies/co-immunoprecipitates with elongation factor 1-alpha (EF1A). Co-incubation of recombinant LRRK2 and EF1A significantly reduces the kinase activity of LRRK2, whereas its GTPase activity remains unchanged. In addition to its canonical role in mRNA translation, EF1A maintains stability of the microtubule cytoskeleton. In the present study, EF1A promotes microtubule assembly in an in vitro tubulin polymerization assay which is impaired by co-incubation with LRRK2 at sub-stoichiometric concentrations. These findings suggest that the interaction between LRRK2 and EF1A may reciprocally modulate their physiological function. (C) 2009 IBRO. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:533 / 539
页数:7
相关论文
共 50 条
  • [21] Role and mechanism of action of leucine-rich repeat kinase 1 in bone
    Weirong R Xing
    Helen Goodluck
    Canjun Zeng
    Subburaman Mohan
    Bone Research, 5
  • [22] Evaluation of Current Methods to Detect Cellular Leucine-Rich Repeat Kinase 2 (LRRK2) Kinase Activity
    Fernandez, Belen
    Chittoor-Vinod, Vinita G.
    Kluss, Jillian H.
    Kelly, Kaela
    Bryant, Nicole
    Nguyen, An Phu Tran
    Bukhari, Syed A.
    Smith, Nathan
    Ordonez, Antonio Jesus Lara
    Fdez, Elena
    Chartier-Harlin, Marie-Christine
    Montine, Thomas J.
    Wilson, Mark A.
    Moore, Darren J.
    West, Andrew B.
    Cookson, Mark R.
    Nichols, R. Jeremy
    Hilfiker, Sabine
    JOURNAL OF PARKINSONS DISEASE, 2022, 12 (05) : 1423 - 1447
  • [23] Differential Effects of Divalent Manganese and Magnesium on the Kinase Activity of Leucine-Rich Repeat Kinase 2 (LRRK2)
    Lovitt, Brian
    VanderPorten, Erica C.
    Sheng, Zejuan
    Zhu, Haitao
    Drummond, Jake
    Liu, Yichin
    BIOCHEMISTRY, 2010, 49 (14) : 3092 - 3100
  • [24] Targeting leucine-rich repeat kinase 2 in Parkinson's disease
    Chan, Sharon L.
    Angeles, Dario C.
    Tan, Eng-King
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2013, 17 (12) : 1471 - 1482
  • [25] Leucine-rich repeat kinase 2: Relevance to Parkinson's disease
    Guo, Luxuan
    Wang, Wen
    Chen, Shu G.
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2006, 38 (09): : 1469 - 1475
  • [26] Role of leucine-rich repeat kinase 2 in severe acute pancreatitis
    Otsuka, Yasuo
    Minaga, Kosuke
    Kudo, Masatoshi
    Watanabe, Tomohiro
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [27] Anatomical localization of Leucine-rich repeat kinase 2 in mouse brain
    Melrose, H
    Lincoln, S
    Tyndall, G
    Dickson, D
    Farrer, M
    NEUROSCIENCE, 2006, 139 (03) : 791 - 794
  • [28] Leucine-rich repeat kinase 2 and lysosomal dyshomeostasis in Parkinson disease
    Cogo, Susanna
    Manzoni, Claudia
    Lewis, Patrick A.
    Greggio, Elisa
    JOURNAL OF NEUROCHEMISTRY, 2020, 152 (03) : 273 - 283
  • [29] Leucine-Rich Repeat Kinase 2 for Beginners: Six Key Questions
    Kett, Lauren R.
    Dauer, William T.
    COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2012, 2 (03):
  • [30] Identification of compounds that inhibit the kinase activity of leucine-rich repeat kinase 2 (vol 378, pg 473, 2009)
    Covy, Jason P.
    Giasson, Benoit I.
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2009, 387 (02) : 419 - 420